Protara Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
TARA$2.51+9.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
| (a) | There is no information that was required to be disclosed in a report on Form 8-K during the fourth quarter of 2025 but was not reported. |
| (b) | Insider trading arrangements The following table provides information concerning Rule 10b5-1 trading arrangements (as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934) adopted in the fourth quarter of 2025 by any director or any executive officer who is subject to the filing requirements of Section 16 of the Securities Exchange Act of 1934. These trading arrangements are intended to satisfy the affirmative defense of Rule 10b5-1(c). These trading arrangements permit transactions through and including the earlier to occur of (a) the completion of all purchases or sales or (b) the date listed in the table below. These trading arrangements, identified as “Rule 10b5-1 Trading Arrangements”, only permit transactions upon expiration of the applicable mandatory cooling-off period under Rule 10b5-1. |
| Name | Title | Adoption Date | Duration | Aggregate number of shares of common stock to be purchased or sold pursuant to the trading arrangement |
|---|---|---|---|---|
| Jesse Shefferman | President, Chief Executive Officer and Director | December 25, 2025 | March 25, 2026 – September 24, 2026 | 69,448 |
| Jacqueline Zummo | Chief R&D Officer | December 31, 2025 | April 1, 2026 – December 31, 2026 | 23,732 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.